9.29
0.83 (9.81%)
| Previous Close | 8.46 |
| Open | 8.45 |
| Volume | 1,088,242 |
| Avg. Volume (3M) | 1,158,631 |
| Market Cap | 787,750,208 |
| Price / Book | 7.67 |
| 52 Weeks Range | |
| Earnings Date | 23 Dec 2024 |
| Diluted EPS (TTM) | -0.520 |
| Current Ratio (MRQ) | 12.04 |
| Operating Cash Flow (TTM) | -30.00 M |
| Levered Free Cash Flow (TTM) | -19.06 M |
| Return on Assets (TTM) | -20.43% |
| Return on Equity (TTM) | -30.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Anavex Life Sciences Corp. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.05% |
| % Held by Institutions | 32.03% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (EF Hutton, 395.16%) | Buy |
| 46.00 (D. Boral Capital, 395.16%) | Buy | |
| Median | 46.00 (395.16%) | |
| Low | 42.00 (HC Wainwright & Co., 352.10%) | Buy |
| Average | 44.67 (380.84%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 9.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Dec 2024 | 42.00 (352.10%) | Buy | 10.87 |
| 27 Nov 2024 | 40.00 (330.57%) | Buy | 9.03 | |
| D. Boral Capital | 23 Dec 2024 | 46.00 (395.16%) | Buy | 11.18 |
| 26 Nov 2024 | 46.00 (395.16%) | Buy | 9.04 | |
| EF Hutton | 31 Oct 2024 | 46.00 (395.16%) | Buy | 6.62 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |